XML 83 R73.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENTS – RELATED PARTIES (Details Narrative) - USD ($)
9 Months Ended
Jun. 15, 2021
Mar. 12, 2021
Sep. 30, 2021
Jun. 30, 2021
Jun. 11, 2021
Jun. 04, 2021
Apr. 13, 2021
Mar. 09, 2021
Feb. 25, 2021
IPO [Member]                  
Shares Issued, Price Per Share $ 5.00                
Shares, Issued 2                
Redemption Premium $ 10,000,000                
Alzamend [Member]                  
[custom:FinancingReceivableFaceAmount-0]     $ 50,000            
Loan Agreement [Member]                  
Debt Instrument, Face Amount           $ 20,000,000 $ 15,000,000    
Securities Purchase Agreement [Member]                  
Shares Issued, Price Per Share         $ 2.99        
Avalanche International Corp [Member]                  
Unrealized Gain (Loss) on Investments     7,700,000            
Avalanche International Corp [Member] | Convertible Promissory Note Ten [Member]                  
[custom:FinancingReceivableFaceAmount-0]     16,600,000            
Avalanche International Corp [Member] | Philou Ventures L L C [Member]                  
[custom:FinancingReceivableFaceAmount-0]     $ 16,500,000            
Secured promissory note     12.00%            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     33.1            
[custom:FinancingReceivableConversionPrice-0]     $ 0.50            
Warrants and Rights Outstanding, Term     5 years            
Avalanche International Corp [Member] | Philou Ventures L L C [Member] | Ownership [Member]                  
Noncontrolling Interest, Ownership Percentage by Parent     1800.00%            
Alzamend [Member]                  
Secured promissory note     8.00%            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     16,667            
Warrants and Rights Outstanding, Term       5 years          
Short-term Investments     $ 750,000            
Alzamend [Member] | Securities Purchase Agreement [Member]                  
[custom:FinancingReceivableFaceAmount-0]               $ 800,000  
[custom:InvestmentInCommonStockAndWarrants]   $ 10.0              
[custom:DescriptionOfReamainingFundedAmount]   The remaining $6.0 million will be funded upon Alzamend achieving certain milestones related to the U.S. Food and Drug Administration approval of Alzamend’s Investigational New Drug application and Phase 1a human clinical trials for Alzamend’s lithium based ionic cocrystal therapy, known as AL001.              
[custom:DescriptionOfAgreement]   Alzamend has agreed to sell up to 6,666,667 shares of its common stock to DP Lending for $10.0 million, or $1.50 per share, and issue to DP Lending warrants to acquire 3,333,334 shares of Alzamend common stock with an exercise price of $3.00 per share.              
Ault And Company Inc [Member]                  
Secured promissory note                 8.00%
Debt Instrument, Face Amount                 $ 2,500,000